Adjuvant Systemic Therapy
AIs beyond five years?
For a 67-year-old patient, would you continue an AI after five years of treatment with an AI if the patient originally had:
<Age 40, ER+, multiple node+ — Endocrine choice?
<Age 40, ER+, multiple node+ — Endocrine choice?
Postmenopausal patient with prior tamoxifen — AI?
ATAC trial 100-month update – Carryover effect: Increased absolute difference between tamoxifen and anastrozole that favors anastrozole at five years and nine years of follow-up
Premenopausal woman with positive nodes — More than 5 years of tamoxifen?
In your opinion, what is the impact on cancer recurrence when adjuvant therapy with tamoxifen is extended beyond 5 years?
Triple-negative with residual tumor after neoadjuvant AC
taxane — Postop Rx?
Triple-negative with residual tumor after neoadjuvant AC
taxane — Postop Rx?
NSABP-B-45 schema (proposed trial)
ER+, HER2-negative, node-negative — Chemo?
TAILORx: A Phase III randomized trial of adjuvant combination chemotherapy and hormonal therapy versus adjuvant hormonal therapy alone in women with previously resected axillary node-negative breast cancer with an intermediate score of the Onco
type
DX assay
TAILORx: A Phase III randomized trial of adjuvant combination chemotherapy and hormonal therapy versus adjuvant hormonal therapy alone in women with previously resected axillary node-negative breast cancer with an intermediate score of the Onco
type
DX assay (Continued)
ER+, HER2-negative, node-negative — Chemo?
HER2-negative, node-negative — Chemo?
ER+, HER2-negative, node-negative — Chemo? Would you recommend chemotherapy for patients who are not eligible for a clinical trial and are in each of the following clinical situations?
ER+, HER2-negative, node-negative — Chemo? What would be your most common chemotherapy treatment recommendation for a patient with an ER-positive, node-negative, HER2-negative tumor who is not eligible for a clinical trial and for whom chemotherapy will be used?
ER+, HER2-negative, node-negative — Chemo? What would be your most common chemotherapy treatment recommendation for a patient with an ER-positive, node-negative, HER2-negative tumor who is not eligible for a clinical trial and for whom chemotherapy will be used?
ER+, HER2-negative, node+ — Chemo?
ER+, HER2-negative, node+ — Chemo? What would be your most common chemotherapy treatment recommendation for a patient with an ER-positive, node-positive, HER2-negative tumor who is not eligible for a clinical trial and for whom chemotherapy will be used?
ER+, HER2-negative, node+ — Chemo? What would be your most common chemotherapy treatment recommendation for a patient with an ER-positive, node-positive, HER2-negative tumor who is not eligible for a clinical trial and for whom chemotherapy will be used?
Prior dose-dense AC
T; now with triple-negative new cancer — Chemo?
Prior dose-dense AC
now with triple-negative new cancer — Chemo?
HER2+, small node-negative — Chemo?
HER2+, small node-negative — Chemo?
> Age 65, HER2+, node+ — Choice of chemo
> Age 65, HER2+, node+ — Choice of chemo
BETH: Proposed NSABP/CIRG adjuvant trial in patients with HER2-positive breast cancer
BETH: Proposed NSABP/CIRG adjuvant trial in patients with HER2-positive breast cancer
> Age 75, ER+, HER2+, node+ — Chemo?
> Age 75, ER-negative, HER2+, node+ — Chemo?
taxane — Postop Rx?
